Latest Breaking News On - Prnewswire alterity therapeutics limited - Page 1 : comparemela.com

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

/PRNewswire/ Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease.

United statesNew zealandNew south walesUnited kingdomSan franciscoDavid stamlerVanderbilt university medical centerAmerican autonomic societyHuman research ethics committeePrnewswire alterity therapeutics limitedMeeting of the american neurological associationTrademark officeCompany american depositary sharesNasdaq stock marketAlterity therapeuticsTherapeutics limited

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

/PRNewswire/ Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease.

United statesSan franciscoPrnewswire alterity therapeutics limitedAlterity therapeuticsTherapeutics limitedAmerican depository sharesOrdinary sharesNasdaq capital marketNew york mellon

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)
kualalumpurtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kualalumpurtimes.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoPrnewswire alterity therapeutics limitedAlterity therapeuticsTherapeutics limitedAmerican depository sharesOrdinary sharesNasdaq capital marketNew york mellon

Appendix 4C - Q1 FY23 Quarterly Cash Flow Report

First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and AustraliaApproval of Investigational New Drug a.

United statesNew zealandUnited kingdomSan franciscoDavid stamlerNational institute of healthAmerican neurological association annual meetingSystem atrophy coalitionHealth biotechItalian medicines agencyAlterity therapeuticsMovement disordersCompany phaseCompany american depositary shares adssPrnewswire alterity therapeutics limitedDrug administration

Appendix 4C - Q1 FY22 Quarterly Cash Flow Report

/PRNewswire/ Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease.

United statesSan franciscoDaniel claassenDavid stamlerPrnewswire alterity therapeutics limitedDrug administrationProfessor of neurology at vanderbilt universityMovement disorder society congressEuropean medicines agencySecurities exchangeInternational parkinsonAlterity therapeuticsMovement disorder societyTherapeutics limitedQuarterly cash flow reportMultiple system atrophy